Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1417  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded424    
    Comments [Add]    
    Cited by others 9    

Recommend this journal


Year : 2007  |  Volume : 55  |  Issue : 3  |  Page : 301--303

Response of central nervous system aspergillosis to voriconazole

Department of Neurology, PSG Institute of Medical Sciences and Research, Avinasi Road, Peelamedu, Coimbatore - 641 002, India

Correspondence Address:
Prakash Balasubramaniam
89-A, East Lokamanya Street, RS Puram, Coimbatore - 641 002, Tamilnadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.35694

Rights and Permissions

Fungal infections of the central nervous system (CNS) usually present as subacute meningitis. Other manifestations include mass effect and focal neurological deficits. [1] Cerebrospinal fluid (CSF) examination and biopsy of the lesion are helpful in disclosing the organism involved. Aspergillosis presents as brain abscess or granuloma with predominant neutrophils in CSF. Voriconazole is a broad spectrum triazole antifungal agent. It can be given orally and has lesser adverse effects We report a 69-years-old diabetic male, with aspergilloma of para-nasal sinus invading the CNS, who responded well to voriconazole treatment. He discontinued the medication by himself as it was costly. Within a month of stopping the medication, he developed features of subacute meningitis. However he showed clinical improvement after the medication was restarted. The case is reported for the clinical evidence of antifungal activity of voriconazole against aspergillosis.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow